TITLE

Tacrolimus -- finally!

AUTHOR(S)
Herrlinger, K. R.; Fellermann, K.; Stange, E. F.
PUB. DATE
September 2006
SOURCE
Gut;Sep2006, Vol. 55 Issue 9, p1224
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article cites a study conducted by researcher H. Ogata and colleagues which examines the use of starlings in patients with refractory ulcerative colitis. The efficacy analysis included sixty patients of whom 15 were steroid resistant. High trough, low trough level and placebo groups achieved in 68, 38 and 10 percent improvement respectively. Seventy-three percent of patients achieved endoscopies healing.
ACCESSION #
22184099

 

Related Articles

  • The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. Naganuma, Makoto; Fujii, Toshimitsu; Watanabe, Mamoru // Journal of Gastroenterology;Feb2011, Vol. 46 Issue 2, p129 

    Background: Intravenous cyclosporine A (CsA) is an effective treatment for patients with severe, steroid-refractory ulcerative colitis (UC). Like the response to CsA, clinical trials have shown that two-thirds of patients with refractory UC respond to tacrolimus therapy. However, it is unclear...

  • Tacrolimus.  // Reactions Weekly;6/8/2013, Issue 1456, p34 

    The article presents case studies of patients who developed de novo inflammatory bowel diseases while taking tacrolimus.

  • Steroid resistance in IBD: how big is the problem?  // Gut;Nov2006, Vol. 55 Issue 11, p1639 

    The article presents the study on the resistance of steroid in inflammatory bowel disease. Patients with ulcerative colitis and Crohn disease were evaluated, who were diagnosed at the Western General Hospital in Edinburgh, Scotland. The results show that corticosteroids are used for more often...

  • A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Ogata, H.; Matsui, T.; Nakamura, M.; Lida, M.; Takazoe, M.; Suzuki, Y.; Hibi, T. // Gut;Sep2006, Vol. 55 Issue 9, p1255 

    Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several...

  • Steroid-Refractory Severe Ulcerative Colitis. Moss, Alan C.; Peppercorn, Mark A. // Drugs;2008, Vol. 68 Issue 9, p1157 

    Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative...

  • Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease—A Long-Term Follow-Up. Baumgart, Daniel C.; Pintoffl, Jan P.; Sturm, Andreas; Wiedenmann, Bertram; Dignass, Axel U. // American Journal of Gastroenterology;May2006, Vol. 101 Issue 5, p1048 

    OBJECTIVE: We and others have reported the use of tacrolimus in refractory inflammatory bowel disease (IBD). Little is known about its long-term efficacy and safety. METHODS: In this retrospective, observational single center study the charts of 53 adult patients with steroid-dependent (n = 18)...

  • Immunization status in children with inflammatory bowel disease. Longuet, Romain; Willot, Stephanie; Giniès, Jean-Louis; Pélatan, Cecile; Breton, Estelle; Segura, Jean-François; Bridoux, Laure; Henaff, Gaelle; Cagnard, Benoit; Jobert, Agathe; Cardonna, Joël; Grimal, Isabelle; Balençon, Martine; Darviot, Estelle; Delaperrière, Nadège; Caldari, Dominique; Piloquet, Hugues; Dabadie, Alain // European Journal of Pediatrics;May2014, Vol. 173 Issue 5, p603 

    Inflammatory bowel diseases have an increased risk of infections due to immunosuppressive therapies. To report the immunization status according to previous recommendations and the reasons explaining a delay, a questionnaire was filled in by the pediatric gastroenterologist, concerning...

  • A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8 × 108 Erythrocytes Predicts Azathioprine Refractoriness in Patients With Inflammatory Bowel Disease and Normal TPMT Activity. Roblin, Xavier; Biroulet, Laurent P.; Phelip, Jean M.; Nancey, Stéphane; Flourie, Bernard // American Journal of Gastroenterology;Dec2008, Vol. 103 Issue 12, p3115 

    BACKGROUND AND AIMS: A therapeutic level of 6-thioguanine nucleotides (6-TGN) has been reported in inflammatory bowel disease (IBD) patients under azathioprine (AZA). We investigated the threshold value of 6-TGN that may be predictive of AZA refractoriness and its impact on safety...

  • Successful twin pregnancy in a patient with ulcerative colitis using azathoprine during conception. Casella, Giovanni; Villanacci, Vincenzo; Antonelli, Elisabetta; Di Bella, Camillo; Baldini, Vittorio; Nejad, Mohammad Rostami; Bassotti, Gabrio // Gastroenterology & Hepatology from Bed to Bench;Oct2011, Vol. 4 Issue 4, p224 

    Inflammatory bowel disease (IBD) frequently affects young patients of childbearing age. Treatments for inflammatory bowel disease include immunosuppressive, cytotoxic and surgical therapies. Azathioprine is frequently used to treat patients with steroid dependent IBD. We report the case of a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics